Overview
ARVN market data
Price History
ARVN price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for ARVN. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
8-K filing — ARVINAS, INC. (ARVN)SEC EDGAR · Jun 22, 2026, 8:10 PM
Rigel Pharmaceuticals Closes Its Licensing Agreement for VEPPANU; The Agreement Is Effective As Of June 11, 2026 And Rigel Has Made The Upfront Payment Of $70.0M To Be Distributed Evenly Between Arvinas And Pfizer, Consistent With The Terms Of The AgreementBenzinga · Jun 16, 2026, 8:10 PM
Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s DiseaseGlobenewswire Inc · Jun 4, 2026, 12:15 PM
Arvinas Announces Re-Prioritization Of Portfolio Following Strategic Review; Plans To Complete Phase 1 Monotherapy Dose Escalation Trial And Share Data In 2026; Plans To Seek Out-Licensing Agreement For Additional Clinical Trials Of ARV-806; Expects Cash Position As Of March 31, 2026 To Fund Operations Into Second Half Of 2028Benzinga · Jun 2, 2026, 8:48 PM
Full Transcript: Arvinas Q1 2026 Earnings CallBenzinga · Jun 1, 2026, 11:56 AM
ESR1-Mutated Metastatic Breast Cancer Market Expected to Grow Rapidly at 9.6% CAGR During the Forecast Period (2026–2036) Due to the Emergence of Novel Oral SERDs and Targeted Agents | DelveInsightGlobenewswire Inc · May 20, 2026, 5:15 PM
These Analysts Increase Their Forecasts On Arvinas After Q1 ResultsBenzinga · May 13, 2026, 5:54 PM
Barclays Maintains Overweight on Arvinas, Raises Price Target to $20Benzinga · May 13, 2026, 2:12 PM
Aramark To Rally Around 20%? Here Are 10 Top Analyst Forecasts For WednesdayBenzinga · May 13, 2026, 1:03 PM
BTIG Maintains Buy on Arvinas, Raises Price Target to $18Benzinga · May 13, 2026, 11:15 AM